Coordination of the activities of different cells in the body is vital for multi-cellular organisms. For this purpose, at least three different types of intercellular communication systems have evolved. Physical interactions between cells through cell surface protein engagement like that between receptors and ligands are used to transmit signals between close, contacting cells ([@B62]; [@B11]). Gap junctions can also facilitate the transmission of molecular signals between cells ([@B78]; [@B91]; [@B37]). Membrane nanotubes or cytonemes that extend up to 100 μm in length are physical connections that also allow communication between cells that are not immediately adjacent to each other ([@B20]). Multi-cellular organisms have also developed a network of circulating body fluids to deliver nutrients to cells, remove waste molecules, and transmit signals for "long-distance" cell--cell and organ--organ communication. The combination of the circulation system with central and peripheral neural networks, and other short and medium range communication processes, allows cells and organs in an organism to operate in close concert. Some circulating proteins or peptides are well-known for their roles as signaling molecules. These include hormones such as insulin, growth hormone, prolactin, and many other secreted proteins/peptides. In addition to these well-known examples, other biomolecules such as nucleic acids are also exported from cells and are present in various body fluids ([@B77]; [@B90]), although their potential roles in intercellular signaling have not been confirmed. While the discovery of circulating extracellular nucleic acid is not new, having been described as early as 1948 ([@B42]), there has been a renewed interest in the function and application of circulating nucleic acids due to several, diverse recent findings. These include the discoveries of fetal DNA in maternal blood ([@B39]), tumor-derived DNA in circulation ([@B30]) and stable regulatory non-coding RNA (ncRNA) in body fluids ([@B14]).

RNA is generally considered to be an unstable molecule that is subject to degradation and turnover by ubiquitous RNase activity. However, intact RNAs of different types, including both protein-coding RNA (mRNA) and non-coding RNA (ncRNA) have been detected in circulation ([@B77]). Some of these RNAs are likely the result of cell lysis through normal cell turnover and are in the process of degradation, reabsorption, or excretion ([@B76]). However, the abundance and high stability of some of these RNA molecules, especially the short regulatory RNA, microRNA (miRNA), suggests a different scenario: the possibility of a cell--cell communication system through RNA-mediated signals ([@B40]; [@B76]; [@B49]). Furthermore, recent studies have shown that exogenous RNA molecules can enter into circulation through the diet or other means, and can potentially be taken up by cells and thereby alter the cellular transcriptome ([@B64]; [@B86]; [@B95]). Many questions remain unanswered, however, including: what are the sources of endogenous and exogenous RNA molecules in circulation, what is (are) the mechanism(s) by which these RNAs enter into circulation, how are they stabilized there, are they taken up by cells, and how are they recognized for uptake by cells? Here we review several recent developments in the study of circulating RNAs and their potential functions and possible applications.

EXTRACELLULAR RNA IN BODY FLUIDS
================================

Among all the circulating nucleic acids, miRNAs are probably the most extensively studied. These small molecules are short, ncRNAs involved in regulating the cellular transcriptome and proteome by destabilizing mRNA and/or attenuating protein translation ([@B19]; [@B18]). The interaction between miRNAs and their cognate mRNA targets is mediated by partial sequence complementarity between the two ([@B18]). The RNA-induced silencing complex (RISC), which contains a number of proteins including members of the Argonaute family, the RNA recognition motif containing protein TNRC6B, putative DNA helicase MOV10, among others, is involved in the miRNA--mRNA interaction ([@B9]).

MicroRNAs were first detected in the blood plasma and serum in 2008 ([@B8]; [@B12]; [@B26]; [@B34]; [@B45]; [@B67]) and have subsequently been detected in many other different body fluids including urine, saliva, tears, and breast milk ([@B54]; [@B21]; [@B90]). The total amount and the concentration of individual miRNAs vary widely among the different fluid types ([@B90]). The potential of circulating miRNAs as biomarkers has been extensively investigated in recent years. miRNAs make good biomarker candidates for several reasons. They are stable in body fluids, which are easy to obtain from patients, they can be easily measured with high sensitivity because they are amplifiable, and some markers and sets of markers have shown profiles associated with specific pathologies. The changes in miRNA levels may be used as a diagnostic tool for several types of cancer ([@B45]; [@B73]; [@B54]; [@B21]; [@B25]; [@B98]; [@B50]; [@B59]), cardiac damage ([@B2]; [@B13]; [@B74]; [@B84]), muscular injury and pathologies ([@B33]; [@B48]; [@B82]), diabetes ([@B8]; [@B17]), liver injury ([@B33]; [@B88], [@B87]; [@B69]), among others.

The literature reporting correlations with human disease and pathologies has grown rapidly in the past few years. The number of papers, for example, on changes in circulating miRNAs in cases of myocardial infarction (MI) and cardiac diseases alone has recently exploded. We estimate that more than 30 reports on this specific topic alone have been published since 2009. Some of the circulating miRNAs identified in MI and cardiac diseases have been summarized in **Table [1](#T1){ref-type="table"}**.

###### 

Circulating miRNAs with biomarker potential to diagnose acute myocardial infarction (AMI).

  Candidate miRNA(s)      Organism       Source                Sample size                                          Correlation                                                                                                                                 Reference
  ----------------------- -------------- --------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -----------
  1, 133a, 133b, 499-5p   Human; mouse   Plasma                33 patients, 17 healthy; 4--5 AMI and control mice   Elevated levels distinguished cardiac damage patients from healthy subjects. Positive correlation with TnI^[a](#fn01){ref-type="fn"}^       [@B15]
  1                       Human; rat     Serum                 31 patients, 20 healthy; 8\~AMI rats, 8 controls     High expression was associated with CK-MB^[b](#fn02){ref-type="fn"}^; positive correlation with myocardial infarct size                     [@B10]
  1                       Human          Plasma                93 patients, 66 healthy                              Up-regulation correlated with QRS^[c](#fn03){ref-type="fn"}^ duration                                                                       [@B2]
  208a                    Human          Plasma                33 patients, 30 healthy                              Present only in patients and showed to be more specific and sensitive than TnI^[a](#fn01){ref-type="fn"}^                                   [@B84]
  208b, 499               Human          Plasma                32 patients, 36 healthy                              High levels correlated with TnT^[d](#fn04){ref-type="fn"}^ and CPK^[e](#fn05){ref-type="fn"}^                                               [@B13]
  499                     Human          Plasma                9 patients, 10 healthy                               Elevated expression correlated positively with CK-MB^[b](#fn02){ref-type="fn"}^ activity                                                    [@B1]
  1, 133a                 Human          Serum                 29 patients, 42 non-AMI                              Increased levels showed correlation with TnT^[d](#fn04){ref-type="fn"}^                                                                     [@B32]
  133, 328                Human          Plasma, whole blood   51 patients, 28 healthy                              High levels correlated with TnT^[d](#fn04){ref-type="fn"}^                                                                                  [@B89]
  30c, 145, 1291, 663b    Human          Whole blood           20 patients, 20 non-AMI                              Elevated levels of 30c and 145 correlated with TnT^[d](#fn04){ref-type="fn"}^; 1291 and 663b distinguished patients from healthy subjects   [@B44]
  208b, 499               Human          Plasma                510 patients, 87 healthy                             Increased levels correlated with peak concentrations of CPK^[e](#fn05){ref-type="fn"}^ and TnT^[d](#fn04){ref-type="fn"}^                   [@B16]
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Efforts have also been made to use circulating miRNAs as a prognostic tool in response to therapeutic treatments ([@B41]). Furthermore, the possibility of using miRNAs as therapeutics themselves has been considered. It is a very exciting prospect if these molecules can be packaged and released into circulation as stable and perhaps even targeted packages. Applications in this area have taken different approaches. For example, creating synthetic miRNAs designed to target specific disease-associated genes, as used by [@B71] to treat heart failure. In this case, viral vectors containing short hairpin RNAs were administered intravenously in rats to reduce the level of a key regulator of cardiac calcium homeostasis, phospholamban ([@B71]). The use of antagomirs to target miRNAs that are upregulated in pathological states has also been demonstrated. For example, an antagomir of miR-133 caused sustained cardiac hypertrophy in mice ([@B7]); antagomirs targeting miR-1 and let-7f were successfully used in rats to extend neuroprotection after ischemic stroke ([@B63]); mice treated with high doses of an antagomir for miR-126 showed reduced ischemia-induced angiogenesis ([@B79]); and a miR-206 antagomir increased brain-derived neurotrophic factor levels and improved memory function in rats with Alzheimer's disease ([@B36]). Furthermore, a treatment for hepatitis C virus (HCV) chronic infection using an antagomir for the liver-specific miR-122 is currently in clinical trial ([@B28]).

RNA EXPORT, PACKAGING, AND UPTAKE
=================================

While extracellular RNAs were first thought to be molecular debris released by cell lysis ([@B76]), the difference in the spectrum of RNA within cultured cells and the external medium argues strongly for selective export of some fraction of the circulating RNAs ([@B85]). It remains unclear how specific RNAs are targeted for export, and if some are simply released with the cytosol through bulk exocytosis. As free RNA molecules are very likely to be degraded outside the cell, it is generally assumed that circulating RNAs are packaged in some form to avoid RNase degradation. Lipid vesicles, such as exosomes or microvesicles are one type of packaging system used by secreted RNAs ([@B77]; [@B6]). Exosomes, which are approximately 30--100 nm in diameter, are formed by fusion of multivesicular bodies with the plasma membrane. Microvesicles are larger (100 nm--1 μm) and formed by blebbing of the plasma membrane. Both types of vesicles can contain a number of protein and RNA molecules, although the composition varies widely with the origin of the vesicle ([@B51]; [@B24]).

In addition to lipid vesicles, it has been demonstrated that miRNA in the extracellular environment can complex with high-density lipoproteins (HDL) and at least two RNA-binding proteins *in vivo*, Argonaute 1 (AGO1) and Argonaute 2 (AGO2), and with nucleophosmin 1 (NPM1) *in vitro* ([@B85]; [@B3]; [@B76]; [@B81]; [@B75]; [@B83]). Furthermore, the spectrum of miRNA associated with HDL depends on the health status of an individual ([@B81]). However, it is not known if there are other RNA-binding proteins that form similar complexes to protect miRNAs or other types of RNA in circulation.

Besides miRNAs, lipid vesicles also contain a large number of protein-coding RNAs. Roughly 1300 different mRNA transcripts have been identified in lipid vesicles derived from human or mouse cell lines ([@B77]). Interestingly, the mRNA composition and abundance in the exosomes differ from that of the original cell, which suggests the contents in the lipid vesicles are selectively packaged rather than included indiscriminately. The levels of circulating miRNAs as well as several mRNAs in circulation have been shown to be associated with stages and types of cancers ([@B72]; [@B45]; [@B73]; [@B52]; [@B98]; [@B96]), pregnancy ([@B101]; [@B57]; [@B92]; [@B99]; [@B23]), and drug-induced liver injury ([@B47]; [@B33]; [@B88], [@B87]; [@B4]; [@B70]; [@B53]).

The idea of using RNA as a mode of intercellular communication is particularly interesting for several reasons. First, RNA can carry information in a simple and efficient way (such as coding for proteins in mRNA), and, second, it can coordinate cellular activity in a fundamental and essential manner (such as microRNA-mediated transcriptome and proteome regulation). It has been demonstrated that cells can export miRNAs, which can be transferred to and are functional in recipient cells ([@B31]; [@B97]; [@B22]). However, it is inherently difficult to test definitively the functioning of an RNA-based communication system *in vivo*. Conditioned media exchange and co-culture experiments have been used to investigate cell--cell communications, and these methods have been adapted to investigate the possibility of RNA uptake by cells ([@B38]; [@B80]; [@B93]). Some exosome-derived mRNAs have been shown to be functional in recipient cells ([@B77]; [@B27]). Furthermore, [@B58] showed that microvesicles derived from embryonic stem cells can enhance the survival and expansion of mouse hematopoietic progenitor cells, and are enriched in stem cell related transcripts including Oct-4, Rex-1, Nanog, SCL, and GATA-2. Reporter assays have shown that exosome-derived miRNAs can silence transcripts in recipient cells ([@B40]; [@B77]; [@B6]; [@B29]; [@B46]). While evidence suggests that cultured cells can transfer packaged RNA molecules, it is difficult to demonstrate this as a general mechanism *in vivo*. One of the most important remaining biochemical questions is how the RNA in circulation is protected, packaged, and delivered to and recognized by their targets. The current lack of knowledge about these questions makes the study of the biological functions of circulating RNA both important and difficult.

Besides protein-coding RNAs and miRNAs, there are other more abundant types of regulatory RNA molecules, such as large intergenic ncRNAs (lincRNAs) and small nucleolar RNAs (snoRNAs) in extracellular vesicles ([@B24]). A recent characterization of neuronal exosomes found RNAs derived from repeat sequences, as well as mRNA and several types of small RNAs. While a majority of small RNA was tRNA (90%), other types of small RNAs including miRNA, snoRNA, and small cytoplasmic RNA (scRNA) were also detected ([@B5]). Since both mRNA and miRNA can be taken up and utilized by cells (see earlier paragraph), there is no reason to think that other types of RNA in circulation do not also have functional implications when they are taken up by cells. However, there is currently no direct experimental evidence to support this functional possibility for other types of RNA in circulation.

METHODS USED IN STUDYING RNA IN CIRCULATION
===========================================

Microarray, qPCR (quantitative polymerase chain reaction), and sequencing-based approaches are the three major platforms that have been used for miRNA and mRNA profiling. All of these have been widely and successfully applied in assessing the spectra of mRNA and miRNA in cells and tissues. However, due to the relatively low concentration of RNA present in circulation, comprehensive measurement of any circulating RNA is difficult to do accurately and consistently. For miRNAs, the difficulties are compounded by the short lengths of the RNA molecules and the consequent sequence specificity of hybridization free energies. At the moment, the most commonly used method for miRNA profiles is qPCR because of its sensitivity and the limited number of known miRNAs (on the order of 1000 sequences). This method has significant drawbacks as well because of the specificity and differential amplification efficiency of the designed primers. This technique has also been applied to measure the level of specific mRNA sequences in circulation ([@B87]). Although microarrays have been the gold standard for transcriptome analysis in cells and tissues, the low concentration of RNA in circulation, and the sequence similarity of these short nucleic acid molecules make microarray analysis unsuitable in most cases. The development of next generation sequencing (NGS) has shown promise in measuring circulating RNAs. This platform not only solves some of the miRNA measurement problems related to short and highly similar sequences of miRNAs, but it can provide measurements on a broad spectrum of RNA in a single experiment. Because it does not rely on pre-designed probes or primers, NGS also allows the identification of novel RNA sequences, such as isomirs and exogenous RNAs in circulation ([@B35]; [@B84], [@B86]; [@B64]). One difficulty with this method is the inherent bias in the preparation of the sequencing libraries. For this reason, absolute measurements of circulating RNA are very difficult, but when carefully done, comparative measurements can be reliable.

EXOGENOUS RNA IN CIRCULATION
============================

Recent evidence, which we discuss below, suggests that RNAs in circulation are derived not only from cells within the human body, but also from foreign organisms and viruses ([@B43]; [@B55]). It has been shown that exogenous RNAs find their way from the outside environment, through diet or from the complex human microbiome ([@B95]). Little is known about how exogenous RNAs are taken up by the gut epithelium from the environment, and there is only very limited and circumstantial evidence so far that these RNAs are functional in the body. However, in keeping with the substantial and growing body of evidence that some human circulating RNA are functional, the possibility that exogenous RNAs, found in the circulation can be taken up and exert specific functions in recipient cells, raises several interesting issues.

A recent report by [@B95] indicated that exogenous miRNAs ingested from food (rice in this case) could enter into the human circulation and be taken up by and actually function in cells. They found that certain plant miRNAs, including miR-168a, an abundant miRNA in rice, is detectable in human plasma, as well as in plasma from other animals eating a diet containing plant material. However, many questions such as how the RNA survives the cooking process and the harsh environment of the digestive tract, as well as how these biomolecules can pass through the gut epithelium, remain largely unanswered. Using Caco-2 cells transfected with synthetic rice miR-168a, [@B95] found that transfected miR-168a can be packaged by cells into microvesicles and released into culture medium. Furthermore, their work suggests that the microvesicles containing exogenous miRNA can be taken up by cells and interact with endogenous transcripts both *in vitro* and *in vivo*. Mature miR-168a sequence has significant sequence homology with a liver-expressed transcript, low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) transcript, raising the possibility that it can suppress the expression of LDLRAP1 through the action of the RISC complex. Indeed, mice fed a rice-containing diet have lower level of LDLRAP1 gene expression than mice fed a normal chow diet, suggesting that miR-168a derived from the rice can affect the level of an endogenous mouse transcript ([@B95]).

Recent work by our lab and others have systematically characterized the composition of RNAs in circulation and revealed that some of the circulating RNAs are derived from a variety of exogenous organisms, including the microbiome ([@B64]; [@B86], [@B87]). Using a map-and-remove strategy to analyze small RNA-seq data (after removing sequences mapped to human miRNAs, transcripts, and genomic sequences first), reveals that a significant portion of the total reads are of non-human origin. While some of these exogenous RNAs are derived from the diet, the majority of them are of either fungal or bacterial origins ([@B86]). The sequences detected implicate a wide range of bacterial phyla, including many already known to reside in the gut microbiome. Although there were not significant differences in the plasma RNA spectra between healthy individuals and those with colorectal cancer or ulcerative colitis, differences can be detected in the plasma of people eating different diets, such as a corn-based diet versus a rice-based diet ([@B86]).

While these results raise the interesting possibility that exogenous RNAs taken up from the environment can alter gene expression in the cells of an organism, many questions remain unanswered. How these RNAs pass through the body's epithelial lining barrier and enter the circulation, for example, is still completely unclear. Because of the relatively low levels of exogenous circulating RNA, it seems likely that if the packages containing exogenous RNAs exert a significant biological effect on the body's cells they must be effectively targeted in some way to specific cells or tissues.

Since some miRNAs are highly conserved in metazoans ([@B66]), the finding of diet derived exogenous RNA in circulation raises the interesting possibility that there are RNA-based processes that either induce or avert the development of diseases in humans arising from foreign RNA. For example, changing the levels of certain highly conserved miRNAs, such as miR-21, which has solid pro-proliferation activity ([@B60]; [@B94]), and miR-150 and miR-146, which have strong association with inflammation activities ([@B65]; [@B68]; [@B61]; [@B56]; [@B100]), by uptake of exogenous RNAs with similar activities may affect the initiation and progression of certain diseases.

Although promising both as biomarkers and potential functional impacts, such as for therapeutics, there is still a great deal to be learned about RNA in circulation. This newly recognized class of circulating molecules has the potential to be deeply involved in the symbiotic functioning of the human body and its microbiome. We currently know very little about the potential mechanisms of entry of RNAs into circulation, their mechanisms of action, their packaging and export process, and their targeting and uptake by cells. Technical improvements and standardization in measuring the levels of these RNAs as well as new model experimental systems are needed in order to explore the many facets of the transport, targeting, and function of these RNAs. In summary, the health impact of RNAs in circulation seems likely to be significant, but the field is just beginning to be explored and the investigation of the area of the quantitative characterization and specific biological functions of exogenous RNA is even earlier in its development.
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